JP2019099571A5 - - Google Patents

Download PDF

Info

Publication number
JP2019099571A5
JP2019099571A5 JP2018223465A JP2018223465A JP2019099571A5 JP 2019099571 A5 JP2019099571 A5 JP 2019099571A5 JP 2018223465 A JP2018223465 A JP 2018223465A JP 2018223465 A JP2018223465 A JP 2018223465A JP 2019099571 A5 JP2019099571 A5 JP 2019099571A5
Authority
JP
Japan
Prior art keywords
invention described
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018223465A
Other languages
English (en)
Japanese (ja)
Other versions
JP7461104B2 (ja
JP2019099571A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2019099571A publication Critical patent/JP2019099571A/ja
Publication of JP2019099571A5 publication Critical patent/JP2019099571A5/ja
Application granted granted Critical
Publication of JP7461104B2 publication Critical patent/JP7461104B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018223465A 2017-11-29 2018-11-29 Glp-1受容体アゴニスト作用を持つピラゾロピリジン誘導体を含有する医薬組成物 Active JP7461104B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2017228661 2017-11-29
JP2017228661 2017-11-29

Publications (3)

Publication Number Publication Date
JP2019099571A JP2019099571A (ja) 2019-06-24
JP2019099571A5 true JP2019099571A5 (ru) 2022-01-06
JP7461104B2 JP7461104B2 (ja) 2024-04-03

Family

ID=66975925

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018223465A Active JP7461104B2 (ja) 2017-11-29 2018-11-29 Glp-1受容体アゴニスト作用を持つピラゾロピリジン誘導体を含有する医薬組成物

Country Status (1)

Country Link
JP (1) JP7461104B2 (ru)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110618208A (zh) * 2019-09-10 2019-12-27 威海迪素制药有限公司 一种(s)-(+)-3-羟基四氢呋喃对映异构体含量检测方法
EP4097099A4 (en) 2020-02-07 2023-09-27 Gasherbrum Bio, Inc. HETEROCYCLIC GLP-1 AGONISTS
WO2022048665A1 (en) * 2020-09-07 2022-03-10 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
WO2023016546A1 (en) * 2021-08-12 2023-02-16 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
WO2023220112A1 (en) * 2022-05-11 2023-11-16 Eli Lilly And Company Glp1 tablet compositions
WO2023220109A1 (en) * 2022-05-11 2023-11-16 Eli Lilly And Company Glp1 pharmaceutical compositions

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0313880B8 (pt) * 2002-08-26 2021-05-25 Takeda Pharmaceuticals Co composto
KR20090094336A (ko) * 2006-11-27 2009-09-04 하. 룬트벡 아크티에 셀스카브 헤테로아릴 아미드 유도체
DK2413693T3 (en) * 2009-03-30 2015-11-16 Vtv Therapeutics Llc Substituted azoanthracenderivater, pharmaceutical compositions and methods for use thereof
WO2014122067A1 (en) * 2013-02-06 2014-08-14 Boehringer Ingelheim International Gmbh New indanyloxydihydrobenzofuranylacetic acids
EP2993174A1 (en) * 2014-09-08 2016-03-09 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt GmbH Pyrazolopyridine derivatives and their use in therapy
JOP20190060A1 (ar) 2016-09-26 2019-03-26 Chugai Pharmaceutical Co Ltd مشتق بيرازولو بيريدين له تأثير مساعد لمستقبل glp-1

Similar Documents

Publication Publication Date Title
JP2019030304A5 (ru)
JP2020042034A5 (ru)
JP2020530297A5 (ru)
JP2021502066A5 (ru)
JP2022028828A5 (ru)
JP2022025124A5 (ru)
JP2021185136A5 (ru)
JP2020534795A5 (ru)
JP2021169491A5 (ru)
JP2020007340A5 (ru)
JP2019068846A5 (ru)
JP2020040981A5 (ru)
JP2021028398A5 (ru)
JP2021500894A5 (ru)
JP2021503478A5 (ru)
JP2016196495A5 (ru)
JP2017214405A5 (ru)
JP2020010717A5 (ru)
JP2018135352A5 (ru)
JP2019142968A5 (ru)
JP2018154848A5 (ru)
JP2018111825A5 (ru)
JP2016028081A5 (ru)
JP2021038271A5 (ru)
JP2019536002A5 (ru)